25014-27-1

Usage

Uses

Used in Pharmaceutical Industry:
POLY-GAMMA-BENZYL L-GLUTAMATE is used as a pharmaceutical compound for its potential therapeutic applications. Its unique structure and chemical properties allow it to interact with various biological systems, making it a promising candidate for the development of new drugs and therapies.
Used in Cosmetics Industry:
In the cosmetics industry, POLY-GAMMA-BENZYL L-GLUTAMATE is used as an ingredient in skincare and beauty products due to its ability to enhance skin hydration and improve the overall appearance of the skin.
Used in Research and Development:
POLY-GAMMA-BENZYL L-GLUTAMATE is utilized as a research tool in the field of biotechnology and material science. Its unique properties make it an interesting subject for studying the interactions between macromolecules and their potential applications in various fields.
Used in Drug Delivery Systems:
Similar to gallotannin, POLY-GAMMA-BENZYL L-GLUTAMATE can be employed in the development of novel drug delivery systems. Its chemical properties and solubility in CHCl3 make it a suitable candidate for improving the delivery, bioavailability, and therapeutic outcomes of various drugs.
Used in Material Science:
POLY-GAMMA-BENZYL L-GLUTAMATE's unique structure and properties can be harnessed in the field of material science for the development of new materials with specific characteristics, such as enhanced strength, flexibility, or biodegradability.

Upstream product

• 56-86-0 L-glutamic acid 
• 104-15-4 toluene-4-sulfonic acid 
• 100-51-6 benzyl alcohol 
• 620-05-3 iodomethylbenzene 
• 2791-84-6 L-glutamic acid dibenzyl ester 4-toluenesulfonate 
• 6893-26-1 D-Glutamic acid 
• 617-65-2 Glutamic acid 
• 98-11-3 benzenesulfonic acid 
• 100-39-0 benzyl bromide 
• 23506-06-1 Z(OMe)-Glu(OBzl)-OH 
• 2768-50-5 dibenzyl L-glutamate 

Downstream Products

• 5894-89-3 γ-benzyl α-(4-nitrophenyl) benzyloxycarbonyl-L-glutamate 
• 75179-44-1 (S)-2-((S)-2-{(2S,3S)-2-[2-(2-Chloro-benzyloxycarbonylamino)-acetylamino]-3-methyl-pentanoylamino}-3-methyl-butyrylamino)-pentanedioic acid 5-benzyl ester 
• 105590-97-4 L-glutamic acid γ-benzyl α-tert-butyl ester hydrochloride 
• 84344-29-6 N-Tfa-L-Glu-OMe-γ-Dcha Salt 
• 88219-18-5 N-Troc-γ-benzyl-L-glutamate t-butylamine salt 
• 87248-30-4 N-Carboxyanhydrid of γ-Benzylhydrogenglutamat 
• 5626-54-0 5-oxopyrrolidine-2-carboxanilide 
• 126349-57-3 N-phenyl-N-α-tert-butoxycarbonyl-γ-benzyl ester L-glutamide 
• 5680-86-4 N-benzyloxycarbonyl-5-O-benzyl-L-glutamic acid 
• 119598-29-7 N-(N-benzyloxycarbonyl-O-methyl-L-γ-glutamyl)-D-glutamic acid-5-benzyl ester-1-methyl ester 
• 1340480-93-4 Nα-[4-chlorocinnamoyl-L-alanyl-D-isoglutaminyl]-L-lysine 

Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of desmuramyl dipeptides modified by adamantyl-1,2,3-triazole

Muramyl dipeptide (MDP) is the smallest peptidoglycan fragment able to trigger the immune response. Structural modification of MDP can lead to the preparation of analogs with improved immunostimulant properties, including desmuramyl peptides (DMPs). The aim of this work was to prepare the desmuramyl peptide (L-Ala-D-Glu)-containing adamantyl-triazole moiety and its mannosylated derivative in order to study their immunomodulatory activities in vivo. The adjuvant activity of the prepared compounds was evaluated in a murine model using ovalbumin as an antigen, and compared to the reference adjuvant ManAdDMP. The results showed that the introduction of the lipophilic adamantyl-triazole moiety at the C-terminus of L-Ala-D-Glu contributes to the immunostimulant activity of DMP, and that mannosylation of DMP modified with adamantyl-triazole causes the amplification of its immunostimulant activity.

Preparation method of N-fluorenylmethoxycarbonyl-gamma-(S-triphenylmethyl-cysteamine)-L-glutamic acid

The invention provides a preparation method of N-fluorenylmethoxycarbonyl-gamma-(S-triphenylmethyl-cysteamine)-L-glutamic acid. The preparation method mainly solves the technical problems of complexity, long period, high cost, and low yield of an original process, and comprises the following steps: (1) preparing N-fluorenylmethoxycarbonyl-L-glutamic acid; (2) preparing N-fluorenylmethoxycarbonyl-L-glutamic acid-1-benzyl ester; (3) preparing S-triphenylmethyl cysteamine; (4) preparing N-fluorenylmethoxycarbonyl-gamma-(S-triphenylmethyl-cysteamine)-L-glutamic acid-alpha-benzyl ester; and (5) preparing N-fluorenylmethoxycarbonyl-gamma-(S-triphenylmethyl-cysteamine)-L-glutamic acid. The method is rapid, high in yield and simple in separation and purification, and the used solvent is environment-friendly and is suitable for mass production.

Rhamnolipid inspired lipopeptides effective in preventing adhesion and biofilm formation of Candida albicans

Rhamnolipids are biodegradable low toxic biosurfactants which exert antimicrobial and anti-biofilm properties. They have attracted much attention recently due to potential applications in areas of bioremediation, therapeutics, cosmetics and agriculture, however, the full potential of these versatile molecules is yet to be explored. Based on the facts that many naturally occurring lipopeptides are potent antimicrobials, our study aimed to explore the potential of replacing rhamnose in rhamnolipids with amino acids thus creating lipopeptides that would mimic or enhance properties of the parent molecule. This would allow not only for more economical and greener production but also, due to the availability of structurally different amino acids, facile manipulation of physico-chemical and biological properties. Our synthetic efforts produced a library of 43 lipopeptides revealing biologically more potent molecules. The structural changes significantly increased, in particular, anti-biofilm properties against Candida albicans, although surface activity of the parent molecule was almost completely abolished. Our findings show that the most active compounds are leucine derivatives of 3-hydroxy acids containing benzylic ester functionality. The SAR study demonstrated a further increase in activity with aliphatic chain elongation. The most promising lipopeptides 15, 23 and 36 at 12.5 μg/mL concentration allowed only 14.3%, 5.1% and 11.2% of biofilm formation, respectively after 24 h. These compounds inhibit biofilm formation by preventing adhesion of C. albicans to abiotic and biotic surfaces.

SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF

Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders as well as other disorders.

DIPEPTIDE MIMETICS OF NGF AND BDNF NEUROTROPHINS

The invention relates to compounds having either agonist or antagonist activities for the neurotrophins NGF and BDNF and represented by monomeric or dimeric substituted dipeptides that are analogs of the exposed portions of loop 1 or loop 4 regions of these neurotrophins near or at a beta-turn of the respective loop. N-acylated substituents of these dipeptides are biostereoisomers of the amino acid residues preceding these dipeptide sequences in the neurotrophin primary structure. The dimeric structure is produced advantageously by using hexatnethylenediaanine to which dipeptides are attached via their carboxyl groups. The claimed compounds displayed neuroprotective and differentiation-inducing activities in cellular models and enhanced the amount of phosphorylated tyrosine kinase A and the heat shock proteins Hsp32 and Hsp70 in the concentration range of 10 -9 to 10 -5 M. They also displayed neuroprotective, anti-parkinsonian, anti-stroke, anti-ischemic, anti-depressant and anti-amnestic activities in animal models and were active in experimental models of Alzheimer's disease. These in vivo effects of the claimed compounds are displayed in the dose range of 0.01 to 10 mg/kg when administered intraperitoneally.

A method for preparation of hybrid amphiphilic star copolymer nano micelles

Hybrid amphiphilic star copolymer nano micelles are prepared in the invention. Cage shaped octa(γ-aminopropyl) silsesquioxanes is selected as the inorganic part, and L-glutamic benzyl ester-five membered ring anhydride is ring-opening polymerized by the initiation of amino groups on the surface of cage shaped octa(γ-aminopropyl) silsesquioxanes, producing copolymers with cage shaped octa(γ-aminopropyl) silsesquioxanes as nucleus and poly (L-glutamic-benzyl ester) as arms. The copolymers reacts with monomethoxy poly (ethylene glycol) carboxylic acid by condensation. Finally, the benzyl groups in the side chains of poly (L-glutamic acid-benzyl ester) are converted into hydrazine groups by acylhydrazination to obtain hybrid amphiphilic star copolymer nano micelles. The micelles can load doxorubicin, they are safe to human body and have good application prospects.

NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF

The invention relates to novel Muramyl Dipeptide (MDP) derivative compound of structural Formula-VIII, a process for synthesis, intermediates used in the synthesis and use thereof; wherein R1 and R2 both are hydrogen; or R1 is hydrogen and R2 is alkyl or aryl; or R1 is alkyl or aryl and R2 is hydrogen; or R1 and R2 both are alkyl or aryl (same or different groups); wherein alkyl group constitute C1-C6 alkyl or higher (both linear and branched) with or without heteroatoms; and aryl group constitute phenyl, substituted phenyl, heteraryl, arylalkyl and polynuclear aromatics. These compounds possess excellent pharmacological properties, in particular immunomodulating properties for use as adjuvant in vaccine formulations. These compounds are, particularly useful as adjuvants in vaccines.

NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF

The invention relates to novel Muramyl Dipeptide (MDP) derivative compound of structural Formula-VIII, a process for synthesis, intermediates used in the synthesis and use thereof. R = alkyl (both linear and branched), aryl, substituted aryl, alkoxy alkyl Wherein, R can be both linear and branched alkyl, aryl, substituted aryl and alkoxy alkyl. These compounds possess excellent pharmacological properties, in particular immunomodulating properties for use as adjuvant in vaccine formulations. These compounds are, particularly useful as adjuvants in vaccines.

CHEMICAL SYNTHESIS AND ANTI-TUMOR AND ANTI-METASTATIC EFFECTS OF DUAL FUNCTIONAL CONJUGATE

The present invention discloses chemical synthesis, anti-tumor and anti-metastatic effects of a dual functional conjugate as showed by formula I. In detail, paclitaxel or docetaxol is linked with muramyl dipeptide derivative to form a conjugate, thus dual anti-tumor and anti-metastatic effects are achieved by combination of chemotherapy and immunotherapy. The present invention also discloses that paclitaxel or docetaxol and muramyl dipeptide derivative conjugate is synthesized by combination of solid-phase and solution-phase synthesis, and said conjugate can be used in manufacture of anti-tumor medicaments as proved by reliable bioassays.

Highly stable polyglutamate derivatives/siRNA polyplex efficiently down-relegate survivin expression and augment the efficacy of cisplatin

RNA interfere (RNAi)-based technology holds great promise in cancer treatment. The use of small interfering RNA (siRNA), however, is hampered by its low delivery efficiency in vivo when they are diluted in blood biofluids and in the presence of serum and salt. In this study, we developed the polyglutamate derivative polymer brush, poly(ethyleneglycol) monomethyl ether-b-polyglutamate-g-spermine (mPEG-b-PG-g-spermine, PPGS), which could efficiently deliver survivin-siRNA under ultra-high dilution and in the presence of salt (NaCl 150 mM) and serum (10% FBS), most likely due to its PEG-shelled polymer brush structure. On the contrary, aggregation occurred when PEI/siRNA polyplex dispersed in saline and serum-containing media and PEI polyplex dissociated after making a 256-fold dilution. PPGS/si-survivin polyplex exhibited high cellular uptake efficiency and efficiently down-regulated the expression of survivin mRNA in the cisplatin-resistance of non-small cell human lung adenocarcinoma (A549/DDP) cells in the presence of serum. However, either PEI polyplex or Lipofectmine 2000 complex was unstable in serum and salt-containing media and at high dilution rates, which resulted in their dramatical decrease of cellular uptake and gene-silencing efficiency in these conditions. The PPGS/si-survivin polyplex also exhibited synergistic effects of killing the cancer cells by combination treatment with cisplatin. Therefore, the PPGS gene carrier showed great potential in systemic siRNA delivery, and its combination with chemotherapeutic drug is promising in treating drug resistant cancers.